Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.00 -4.9%	$7.10	$2.05 ▼ $8.72	$749.90M	-0.46	1.02 million shs	782,249 shs
DERM Journey Medical	$6.95 -4.3%	$7.15	$3.54 ▼ $8.90	$169.13M	0.8	175,392 shs	267,426 shs
FBIO Fortress Biotech	$2.12 +8.2%	$1.91	$1.33 ▼ $2.36	$57.96M	1.76	168,314 shs	928,848 shs
PHAT Phathom Pharmaceuticals	$10.24 -2.2%	$9.29	$2.21 ▼ $19.71	$742.78M	0.45	1.08 million shs	845,139 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-4.88%	+4.71%	-5.10%	+65.29%	+275.59%
DERM Journey Medical	-4.27%	-8.19%	-3.47%	+0.29%	+46.01%
FBIO Fortress Biotech	+8.16%	+16.48%	+7.61%	+17.13%	+17.13%
PHAT Phathom Pharmaceuticals	-2.20%	+5.13%	+22.93%	+150.37%	-17.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.5415 of 5 stars	4.5	2.0	2.7	2.5	0.6
DERM Journey Medical	1.8871 of 5 stars	3.5	1.0	2.2	0.8	0.6
FBIO Fortress Biotech	2.3791 of 5 stars	3.5	1.0	1.4	3.3	0.6
PHAT Phathom Pharmaceuticals	3.1263 of 5 stars	3.5	1.0	2.4	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	46.88% Upside
DERM Journey Medical	3.00	Buy	$10.83	55.88% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	890.57% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	70.90% Upside

Current Analyst Ratings Breakdown

Latest DERM, FBIO, PHAT, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $13.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	8.16	N/A	N/A	$1.88 per share	4.26
DERM Journey Medical	$56.13M	2.88	N/A	N/A	$0.83 per share	8.37
FBIO Fortress Biotech	$57.67M	1.09	N/A	N/A	($0.06) per share	-35.33
PHAT Phathom Pharmaceuticals	$55.25M	13.15	N/A	N/A	($5.72) per share	-1.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	N/A	N/A	N/A	N/A	-82.48%	-70.15%	N/A
DERM Journey Medical	-$14.67M	-$0.39	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	N/A
FBIO Fortress Biotech	-$46M	-$1.05	N/A	N/A	N/A	-24.84%	-693.95%	-27.94%	N/A
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	N/A

Latest DERM, FBIO, PHAT, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FBIO Fortress Biotech	-$0.31	-$0.46	-$0.15	$0.45	$14.53 million	$16.41 million
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
DERM Journey Medical	1.11	1.27	1.03
FBIO Fortress Biotech	1.74	1.72	1.55
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
DERM Journey Medical	7.25%
FBIO Fortress Biotech	96.51%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	12.30%
DERM Journey Medical	15.03%
FBIO Fortress Biotech	27.90%
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
PHAT Phathom Pharmaceuticals	110	70.94 million	54.63 million	Optionable

DERM, FBIO, PHAT, and AMLX Headlines

Recent News About These Companies

Phathom Pharmaceuticals (PHAT) Gets a Buy from H.C. Wainwright

August 14 at 10:57 PM | theglobeandmail.com

Phathom Pharmaceuticals (PHAT) Gets a Buy from Guggenheim

August 14 at 10:57 PM | theglobeandmail.com

Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

August 13 at 5:05 AM | msn.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $17.50 Consensus Target Price from Analysts

August 10, 2025 | americanbankingnews.com

Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line

August 9, 2025 | finance.yahoo.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript

August 9, 2025 | insidermonkey.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 11.7% Higher - Here's What Happened

August 8, 2025 | marketbeat.com

Phathom (PHAT) Q2 Revenue Jumps 441%

August 8, 2025 | theglobeandmail.com

Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth

August 8, 2025 | msn.com

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | globenewswire.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Rating of "Buy" by Brokerages

August 7, 2025 | marketbeat.com

XTX Topco Ltd Invests $565,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

August 7, 2025 | marketbeat.com

Craig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)

August 6, 2025 | theglobeandmail.com

Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday

August 1, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7% - Here's Why

July 29, 2025 | marketbeat.com

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

July 28, 2025 | globenewswire.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.2% Higher - Here's Why

July 26, 2025 | marketbeat.com

Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells 1,692 Shares of Stock

July 19, 2025 | marketbeat.com

Robert Charles Breedlove Sells 1,692 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

July 19, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM, FBIO, PHAT, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.00 -0.41 (-4.88%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.11 +0.11 (+1.36%)

As of 08/15/2025 06:50 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Journey Medical NASDAQ:DERM

$6.95 -0.31 (-4.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$6.61 -0.34 (-4.95%)

As of 08/15/2025 07:46 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Fortress Biotech NASDAQ:FBIO

$2.12 +0.16 (+8.16%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.14 +0.02 (+1.18%)

As of 08/15/2025 07:26 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Phathom Pharmaceuticals NASDAQ:PHAT

$10.24 -0.23 (-2.20%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.58 +0.34 (+3.32%)

As of 08/15/2025 06:22 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time